Literature DB >> 15046259

The evolutionary adaptation of HIV-1 to specific immunity.

Jack da Silva1.   

Abstract

Recent evidence of the evolutionary adaptation of HIV-1 to the specific immune system is reviewed. Longitudinal studies of patients show that a neutralizing antibody (NAb) response specific to autologous virus is detectable within 1-2 months of infection and that viral variants resistant to neutralization arise and spread in the viral population within the subsequent three months, and that this general pattern is repeated. There is strong evidence that amino acid replacements in gp120 glycan-binding motifs affect viral sensitivity to neutralization and are selected by NAbs. Longitudinal studies of humans have also provided good evidence of amino acid replacements in cytotoxic T lymphocyte (CTL) epitopes that allow the virus to escape detection by CTLs. But, the clearest evidence of adaptation to CTL surveillance at the molecular level comes from experiments with SIV-infected rhesus macaques. These show unequivocally that amino acid replacements in CTL epitopes are the result of positive selection and that these escape mutants have a lower class I major histocompatibility complex (MHC) binding affinity or are less likely to be recognized by CTLs than non-escape variants. To improve our ability to predict HIV's evolutionary responses to selection by the specific immune system it is suggested that future work focus on the details of the adaptive response to antibody surveillance, the temporal dynamics of specific immune responses, the relative importance of antibody and CTL selection, and the effects of superinfection, viral recombination, and viral protein functional constraints on immune escape.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15046259     DOI: 10.2174/1570162033485249

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  7 in total

1.  The antigenic determinants on HIV p24 for CD4+ T cell inhibiting antibodies as determined by limited proteolysis, chemical modification, and mass spectrometry.

Authors:  Jason G Williams; Kenneth B Tomer; Catarina E Hioe; Susan Zolla-Pazner; Philip J Norris
Journal:  J Am Soc Mass Spectrom       Date:  2006-07-27       Impact factor: 3.109

2.  Arteriviruses, Pegiviruses, and Lentiviruses Are Common among Wild African Monkeys.

Authors:  Adam L Bailey; Michael Lauck; Ria R Ghai; Chase W Nelson; Katelyn Heimbruch; Austin L Hughes; Tony L Goldberg; Jens H Kuhn; Anna J Jasinska; Nelson B Freimer; Cristian Apetrei; David H O'Connor
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

3.  Site-specific amino acid frequency, fitness and the mutational landscape model of adaptation in human immunodeficiency virus type 1.

Authors:  Jack da Silva
Journal:  Genetics       Date:  2006-07-18       Impact factor: 4.562

4.  Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India.

Authors:  Smita Kulkarni; Srikanth Tripathy; Raman Gangakhedkar; Sushama Jadhav; Kalpana Agnihotri; Suvarna Sane; Robert Bollinger; Ramesh Paranjape
Journal:  AIDS Res Hum Retroviruses       Date:  2008-09       Impact factor: 2.205

5.  Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette-Guerin (BCG).

Authors:  Richard Copin; Mireia Coscollá; Sebastien Gagneux; Joel D Ernst; Efstratios Efstathiadis
Journal:  Vaccine       Date:  2014-09-06       Impact factor: 3.641

6.  Functional consequences of human immunodeficiency virus escape from an HLA-B*13-restricted CD8+ T-cell epitope in p1 Gag protein.

Authors:  Julia G Prado; Isobella Honeyborne; Ian Brierley; Maria Carmen Puertas; Javier Martinez-Picado; Philip J R Goulder
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

Review 7.  The Troika Host-Pathogen-Extrinsic Factors in Tuberculosis: Modulating Inflammation and Clinical Outcomes.

Authors:  Helder Novais Bastos; Nuno S Osório; Sebastien Gagneux; Iñaki Comas; Margarida Saraiva
Journal:  Front Immunol       Date:  2018-01-09       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.